✨ Free AI Report
Regulus Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Regulus Therapeutics Inc.
Research Preview

Regulus Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

Regulus Therapeutics was a biotechnology company focused on the development of microRNA therapies targeting diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The company was acquired by...

Analyst-debate audio for Regulus Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for Regulus Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Regulus Therapeutics Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Regulus Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Regulus Therapeutics Inc. Overview

Pro stress-test →

Regulus Therapeutics was a biotechnology company focused on the development of microRNA therapies targeting diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The company was acquired by Novartis with the purchase completed on June 25, 2025, making it now a wholly owned subsidiary of Novartis.

Strategic Profile

Pro stress-test →

The key asset acquired was farabursen, an investigational oligonucleotide targeting the microRNA miR-17 with preferential kidney exposure, intended to treat autosomal dominant polycystic kidney disease (ADPKD). Phase Ib trial results showed farabursen reduced kidney cyst growth and kidney size, supporting its potential as a first-in-class therapy for ADPKD.

Competitive Landscape

Pro stress-test →

Competitors in the broader therapeutic space included Capricor Therapeutics, Inovio Pharmaceuticals, Sorrento Therapeutics, aTyr Pharma, and Kite Pharma. However, as an acquired entity, Regulus' farabursen now competes within Novartis' portfolio against other ADPKD and renal disease therapies.

Industry Context

Regulus Therapeutics Inc. operates in MicroRNA therapeutics.

Key facts

Founded: 2007 · Headquarters: San Diego, US · Employees: 34 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Regulus Therapeutics Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Regulus Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Capricor TherapeuticsGene and cell therapy development→Inovio PharmaceuticalsImmunotherapy and vaccine platform→Kite PharmaCAR-T cell therapy and oncology→

Compare Regulus Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Regulus Therapeutics Inc. operates in MicroRNA therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse MicroRNA therapeutics research →
NEW · MCP server

Ask your AI assistant about Regulus Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Regulus Therapeutics Inc. and its top competitor on Cyborg Score”
“What did Regulus Therapeutics Inc. do this quarter?”
“Is Regulus Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Regulus Therapeutics Inc. do?+
Regulus Therapeutics was a biotechnology company focused on the development of microRNA therapies targeting diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The company was acquired by...
What is Regulus Therapeutics Inc.'s Cyborg Score?+
The Cyborg Score is a 1-10 rating from the AskCyborg multi-agent analyst-debate framework. Recalibrated weekly across business, financials, leadership, competitive position, technology, marketing, and ESG dimensions.
Who are Regulus Therapeutics Inc.'s main competitors?+
Named competitors include Capricor Therapeutics, Inovio Pharmaceuticals, Kite Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Regulus Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Regulus Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Sezzle Inc.9Carpenter Technology Corporation9Credo Technology Group Holding Ltd9TE Connectivity plc9Rheinmetall AG9Northrop Grumman Corporation9Interactive Brokers Group, Inc.9Berkshire Hathaway Inc.9Mastercard Incorporated8Vera Therapeutics, Inc.8Quoin Pharmaceuticals, Ltd.8Prenetics Global Limited8Strattec Security Corporation8Lesaka Technologies Inc.8Abu Dhabi Ship Building PJSC8Judges Scientific plc8Weathernews Inc.8Orrstown Financial Services, Inc.